Meanwhile, another phase I clinical trial is currently evaluating the combination of IMC-CS4 (CSF1R mAb) with pancreatic cancer vaccine (GVAX) and pembrolizumab (anti-PD-1 mAb) in patients with borderline resectable pancreatic cancer (NCT03153410). Here, CSF1R is linked to pancreatic neoplasm.